Human Hemopexin (Native) – Research Use Only

Human Hemopexin (Native) is a high-purity 57 kDa plasma glycoprotein supplied as a 1 mg lyophilized powder (Catalog #B2016890). Hemopexin is the primary heme-binding protein in human plasma. It binds free heme with extremely high affinity, protecting against heme-induced oxidative damage, lipid peroxidation, and endothelial injury while facilitating safe heme recycling in hepatocytes via receptor-mediated endocytosis.

Scientific Overview

Hemopexin is a 57 kDa acute-phase glycoprotein that binds free heme with the highest known affinity of any protein (Kd ~10⁻¹³ M). By sequestering heme, it prevents heme-catalyzed formation of reactive oxygen species, lipid peroxidation, and endothelial damage. The hemopexin-heme complex is cleared by hepatocytes via the CD91/LRP1 receptor, where heme is catabolized by heme oxygenase-1. Hemopexin levels rise during inflammation, hemolysis, and tissue injury, making it both a protective factor and a potential biomarker.

This Native Human Hemopexin is suitable for:

• Heme-binding and transport studies
• Oxidative stress and heme toxicity research
• Acute-phase response and inflammation models
• Development of heme-related biomarker assays
• Investigation of hemopexin–receptor interactions and heme recycling

Usage & Handling Guidance

Store the lyophilized powder at -20 °C. Reconstitute in sterile ultrapure water or PBS to the desired concentration. Prepare single-use aliquots to avoid repeated freeze–thaw cycles. The protein remains stable when handled under standard laboratory conditions.

• Recommended applications: Heme-binding assays, oxidative stress studies, and acute-phase response research
• Working concentration: Optimize empirically (commonly 1–50 µg/mL depending on assay)
• Stability: Lyophilized form is stable at -20 °C; reconstituted solutions should be used promptly or stored frozen
• Handling: Use protease-free conditions; keep on ice during dilution if needed

What You Get

• 1 mg Native Human Hemopexin as a lyophilized powder
• High-purity 57 kDa plasma glycoprotein with native heme-binding capacity
• Biotechnology-grade material suitable for biochemical and immunological studies
• Convenient quantity for multiple experiments and method optimization
• For research use only (RUO)

Why Researchers Choose It

• Native human hemopexin with intact high-affinity heme-binding properties
• Excellent tool for studying heme scavenging, oxidative stress protection, and acute-phase responses
• Useful as a control or standard in hemopexin-related biomarker and functional assays
• Stable lyophilized format with reliable lot-to-lot consistency
• Well-characterized protein with extensive literature support in heme metabolism and inflammation

Frequently Asked Questions (FAQ)

• What is the primary function of hemopexin?
  Hemopexin binds free heme with extremely high affinity, preventing oxidative damage and facilitating safe heme recycling in the liver.
• Why use native human hemopexin?
  The native form retains full biological activity and heme-binding capacity, making it ideal for functional and binding studies.
• How should I reconstitute the powder?
  Dissolve in sterile ultrapure water or PBS to the desired concentration. Prepare aliquots and store at -20 °C to avoid repeated freeze–thaw cycles.
• Can this be used in cell-based assays?
  Yes. It can be added to serum-free or low-serum media for heme-related cellular studies.
• How should I store the product?
  Store the lyophilized powder at -20 °C for long-term stability.

---

References

• Ahmad Y, Sharma NK, Garg I, Ahmad MF, Sharma M, Bhargava K. An insight into the changes in human plasma proteome on adaptation to hypobaric hypoxia. PLoS One. 2013 Jul 2;8(7):e67548.
• von Bonsdorff L, Tölö H, Lindeberg E, Nyman T, Harju A, Parkkinen J. Development of a pharmaceutical apotransferrin product for iron binding therapy. Biologicals. 2001 Mar;29(1):27-37.
• d’Ortho MP, Will H, Atkinson S, Butler G, Messent A, Gavrilovic J, Smith B, Timpl R, Zardi L, Murphy G. Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem. 1997 Dec 15;250(3):751-7.
• Steffensen B, Bigg HF, Overall CM. The involvement of the fibronectin type II-like modules of human gelatinase A in cell surface localization and activation. J Biol Chem. 1998 Aug 7;273(32):20622-8.
• Shoji A, Kabeya M, Sugawara M. Real-time monitoring of matrix metalloproteinase-9 collagenolytic activity with a surface plasmon resonance biosensor. Anal Biochem. 2011 Dec 1;419(1):53-60.
• Liu P, Na N, Huang L, He D, Huang C, Ouyang J. The application of amine-terminated silicon quantum dots on the imaging of human serum proteins after polyacrylamide gel electrophoresis (PAGE). Chemistry. 2012 Jan 27;18(5):1438-43.
• Vincent SH, Grady RW, Shaklai N, Snider JM, Muller-Eberhard U. The influence of heme-binding proteins in heme-catalyzed oxidations. Arch Biochem Biophys. 1988 Sep;265(2):539-50.
• Knäuper V, Cowell S, Smith B, López-Otin C, O’Shea M, Morris H, Zardi L, Murphy G. The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J Biol Chem. 1997 Mar 21;272(12):7608-16.
• Tam EM, Moore TR, Butler GS, Overall CM. Characterization of the distinct collagen binding, helicase and cleavage mechanisms of matrix metalloproteinase 2 and 14 (gelatinase A and MT1-MMP): the differential roles of the MMP hemopexin c domains and the MMP-2 fibronectin type II modules in collagen triple helicase activities. J Biol Chem. 2004 Oct 8;279(41):43336-44.
• Wilhelm SM, Collier IE, Marmer BL, Eisen AZ, Grant GA, Goldberg GI. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem. 1989 Oct 15;264(29):17213-21.